The rapid development of antibiotic resistance has become a major public health issue that could soon kill 10 million people annually. One promising alternative to ineffective antibiotics has been around for almost a century – bacteriophages. The microbe-killing viruses are used in medicine in Georgia, Poland and Russia, but have been neglected by western doctors. Now pressure is mounting on global health authorities to put the option back on the table.
Nouscom Appoints Adrian Woolfson as CMO
AppointmentsNouscom, an immuno-oncology company developing off-the-shelf and personalized neoantigen-based genetic cancer vaccines, announced today the appointment of Adrian Woolfson M.D., Ph.D. as Chief Medical Officer (CMO).
New way to safer CAR-T cell therapies
Latest NewsInterleukin 1 (IL-1) blockers may prevent serious adverse events triggered by CAR-T cell therapies, according to two independent studies.
Janssen ends combo with daratumumab
Latest NewsFollowing reports of an increase in mortality in a study that combined Genmab’s anti-CD38 daratumumab with a PD-L1 blocker, Genmab’s partner Janssen has stopped a study combining daratumumab with its PD1 blocker JNJ-63723283 in multiple myeloma.
Targovax drug boosts 2-year OS in pancreatic cancer
Latest NewsTargovax ASA’s cancer immunotherapy TG01 significantly prolonged 2-year overall survival of patients with resected pancreatic cancer versus standard therapy. Targovax’ shares were up 16% on Thursday evening.
Researchers target metastases
Latest NewsItalian oncologists have found a more effective tumour angiogenesis blocker which curbs metastasis and tumour growth.
Vifor Pharma in €70m pruritus drug deal
Latest NewsVifor Fresenius Medical Care Renal Pharma has licenced ex-US/Japanese/Korean rights to commercialise CR845 (difelikefalin) from Cara Therapeutics for the treatment of chronic kidney disease-associated pruritus (CKD-aP).
Fighting AMR: turning the p(h)age
BackgroundThe rapid development of antibiotic resistance has become a major public health issue that could soon kill 10 million people annually. One promising alternative to ineffective antibiotics has been around for almost a century – bacteriophages. The microbe-killing viruses are used in medicine in Georgia, Poland and Russia, but have been neglected by western doctors. Now pressure is mounting on global health authorities to put the option back on the table.
Evotec signs US$65m deal with Celgene
Latest NewsEvotec AG and Celgene Corporation have entered into a strategic drug discovery and development partnership to identify new therapeutics in oncology.
Aldevron Names Marc Wolff CFO
AppointmentsMarc Wolff has been named Chief Financial Officer of Aldevron, a provider of plasmid DNA manufacturing, protein production and antibody discovery services. Mr. Wolff will lead the global finance and accounting team across all Aldevron sites in the U.S. and Europe.
Biomaterials growth and crash side by side
Latest NewsBioeconomy industry experts gave a mixed outlook for biomaterials in mid-May in Cologne where about 200 stakeholder joined the 11th International Conference on Bio-based Materials.